A DNA sequencing sleuth called CypherSeq by Neves, Alexandre
November 15, 2015 SCIENCE SPOTLIGHT 
 
1 Volume 5, Issue 11 | Fred Hutchinson Cancer Research Center 
 
A DNA sequencing sleuth called CypherSeq 
November 15, 2015 
     A Neves 
 
CypherSeq error correction and detection of rare mutations. A) Base substitutions determined by next-generation 
sequencing with a quality filter. The sample contains four mutations at the sites shown in red, which were spiked into 
the sample at known ratios of one mutant copy in 100, 1000, 10,000, and 100,000 wild type copies. However, due to 
the high background of erroneous substitutions, the real mutations cannot be distinguished from sequencing errors. 
B) Base substitutions determined by sequencing with CypherSeq. The increased accuracy of CypherSeq removes 
the background, allowing accurate and quantitative identification of the four real mutations down to a frequency of ~1 
mutant in 100,000 copies. 
 
Image provided by Dr. Mark Gregory. 
Next-generation sequencing (NGS) technologies have transformed both basic and clinical research, 
as they have enabled the development of diverse applications ranging from pre-natal testing to 
cancer prognosis. However, there are a number of limitations that prevent NGS technologies from 
fulfilling their full potential. These include the inherent error of DNA sequencing instruments, the 
sequencing coverage depth and the amount of available sample DNA required. To address these 
limitations, post-doctoral fellows Drs. Mark Gregory and Jessica Bertout and collaborators in Dr. 
Jason Bielas’ Laboratory (Human Biology and Public Health Sciences Divisions), developed a new 
method called CypherSeq that markedly improved NGS-based detection of rare mutations. This 
exciting report was recently published in the journal Nucleic Acids Research. 
The investigators first designed the CypherSeq vector as a double-stranded barcoded vector that 
can be amplified in bacteria and contains all of the necessary sequences required to perform NGS. 
To delineate the power of the CypherSeq error correction algorithm, the researchers first applied the 
CypherSeq technology to a mixed DNA population with known ratios of both wild-type and four 
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mutant versions of the tumor suppressor gene TP53. This analysis revealed that a single TP53 
mutant could be resolved among more than 10
5
 copies of wild-type TP53, which translates to a 
frequency of 2.4 x 10
-7
 mutations per base pair (see figure) and represents at least a 10-fold 
improvement over other NGS methods. Next, the authors addressed whether CypherSeq could be 
used for genome-wide assessment of both spontaneous and induced mutations. To this end, they 
grew liquid cultures of the baker’s yeast Saccharomyces cerevisiae with or without the mutagen 
ethyl methanesulfonate (EMS). After application of CypherSeq sequencing and computational error-
correction these samples revealed a base substitution frequency of 1.4 x 10
-6
 and 4.6 x 10
-6
 in 
untreated and EMS-treated cultures, respectively, demonstrating a clear increase due to treatment. 
Importantly, the additional mutations seen in the EMS-treated samples were nearly all C to T 
mutations, which match the known mutation signature of the EMS mutagen. As the EMS mutations 
in this experiment would only be present on a single genome within the yeast culture, the accurate 
detection of these mutations represent single cell resolution sequencing. Thus, CypherSeq is a more 
accurate DNA sequencing method that, for the first time, enables genome-wide calculations of 
mutations rates without resorting to single cell approaches.  
Finally, the authors demonstrated that CypherSeq can also efficiently enrich a sequencing library for 
specific genomic sites. Because the CypherSeq vector is circular, rolling circle amplification (RCA) of 
a biotinylated primer was used to generate single-stranded DNA concatemers, which could be 
further enriched with streptavidin affinity purification. Indeed, CypherSeq vectors containing TP53 
sequences in the background of randomly sheared genomic DNA were enriched 977-fold. Such 
enrichment, decreases off-target superfluous sequencing, permits deeper sequencing depth of 
targeted sites, and thus the detection of much rarer variants. In summary, CypherSeq’s highly 
sensitive error correction and RCA-based target enrichment strategies offer tantalizing possibilities 
for cancer diagnostics. Said Dr. Gregory: "Combining highly accurate sequencing with the ability to 
target specific regions of the genome is an important advance which will allow us to investigate rare 
mutations throughout the genome, at a resolution unmatched before. This technology should enable 
the development of a new class of sequencing-based clinical tests, such as noninvasive blood tests 
for early cancer diagnosis, identification of optimal therapeutic approaches, and monitoring of 
treatment response".  
Funding for this study was provided by the National Institutes of Health, the Department of Defense, 
the Canary Foundation, the Marsha Rivkin Center for Ovarian Cancer Research, and the Ellison 
Medical Foundation.    
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